Takeda's patent to produce name brand Vyvanse expired in August 2023. The FDA has authorized approximately a dozen pharmaceutical companies to begin manufacturing generic versions of Vyvanse. 

It could take months or years for some manufacturers to complete quality checks and arrange distribution of their product to pharmacies nationwide. 

Some manufacturers such as Mallinckrodt and Viatris in the United States, Hikma Pharmaceuticals in the United Kingdom and Sun Pharmaceutical Industries in India have already started shipping their generic versions of Vyvanse. ​

Currently there are no "authorized generics" in production so it is yet to be seen how well the generic products will resemble name brand Vyvanse. Generic medications are required to contain the same active ingredient in the same amount as the name brand medication but the other ingredients (binders, fillers, etc) may be different as can be the manufacturing process. These differences can affect how the drug is absorbed and metabolized by the body. 

Authorized generics are exactly the same product as the name brand medication. They contain the same active and inactive ingredients and are manufactured according to the specifications of the original manufacturer but sold with a generic label. Often authorized generics are manufactured by the same company in the same facility as the brand name drug.